160 related articles for article (PubMed ID: 338408)
1. Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-etide response to intravenous glucagon.
Hendriksen C; Faber OK; Drejer J; Binder C
Diabetologia; 1977 Dec; 13(6):615-9. PubMed ID: 338408
[TBL] [Abstract][Full Text] [Related]
2. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus.
Faber OK; Binder C
Diabetes; 1977 Jul; 26(7):605-10. PubMed ID: 326604
[TBL] [Abstract][Full Text] [Related]
3. Diurnal profiles of intermediary metabolites in insulin-dependent diabetes and their relationship to different degrees of residual B-cell function.
Madsbad S; Faber OK; Binder C; Alberti KG; Lloyd B
Acta Diabetol Lat; 1981; 18(2):115-21. PubMed ID: 7018146
[TBL] [Abstract][Full Text] [Related]
4. Failure of indomethacin to affect arginine-induced C-peptide and glucagon release in insulin-treated diabetics. Major role of residual B cell function in conditioning the magnitude of the blood glucose rise after intravenous arginine.
Luyckx AS; Mendoza E; Lefebvre PJ
Diabetologia; 1981 Oct; 21(4):376-82. PubMed ID: 7026333
[TBL] [Abstract][Full Text] [Related]
5. C-peptide response to glucagon in diabetics with and without complications.
Smith RB; Pyke DA; Watkins PJ; Binder C; Faber OK
N Z Med J; 1979 Apr; 89(634):304-6. PubMed ID: 377156
[TBL] [Abstract][Full Text] [Related]
6. Lack of effect of improved glycemic control on C-peptide secretion in patients without residual B-cell function.
Seigler DE; Reeves ML; Skyler JS
Diabetes Care; 1982; 5(3):334-6. PubMed ID: 6756843
[TBL] [Abstract][Full Text] [Related]
7. Residual pancreatic function in insulin dependent diabetics.
Glatthaar C; Beaven DW; Donald RA; Smith JR; Espiner EA
Aust N Z J Med; 1982 Feb; 12(1):43-7. PubMed ID: 7044357
[TBL] [Abstract][Full Text] [Related]
8. Metabolic control and B cell function in patients with insulin-dependent diabetes mellitus secondary to chronic pancreatitis.
Larsen S; Hilsted J; Tronier B; Worning H
Metabolism; 1987 Oct; 36(10):964-7. PubMed ID: 3309547
[TBL] [Abstract][Full Text] [Related]
9. C-peptide response to glucagon in young diabetics.
Juang JH; Huang BY; Huang HS; Lin JD; Huang MJ
Taiwan Yi Xue Hui Za Zhi; 1989 Jun; 88(6):579-83. PubMed ID: 2677232
[TBL] [Abstract][Full Text] [Related]
10. Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects. Postprandial plasma C-peptide level is an indication of insulin dependency.
Prando R; Odetti P; Melga P; Giusti R; Ciuchi E; Cheli V
Diabetes Metab; 1996 Jun; 22(3):185-91. PubMed ID: 8697306
[TBL] [Abstract][Full Text] [Related]
11. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
[TBL] [Abstract][Full Text] [Related]
12. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus.
Madsbad S; Krarup T; McNair P; Christiansen C; Faber OK; Transbøl I; Binder C
Acta Med Scand; 1981; 210(3):153-6. PubMed ID: 7027749
[TBL] [Abstract][Full Text] [Related]
13. Reproducibility of beta-cell function estimates in non-insulin-dependent diabetes mellitus.
Gjessing HJ; Damsgaard EM; Matzen LE; Frøland A; Faber OK
Diabetes Care; 1987; 10(5):558-62. PubMed ID: 3315512
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic beta-cell function in cirrhotic patients with and without overt diabetes. C-peptide response to glucagon and to meal.
Marchesini G; Melli A; Checchia GA; Mattioli L; Capelli M; Cassarani S; Zoli M; Pisi E
Metabolism; 1985 Aug; 34(8):695-701. PubMed ID: 3894876
[TBL] [Abstract][Full Text] [Related]
15. Effect of strict blood glucose control on residual B-cell function in insulin-dependent diabetics.
Madsbad S; Krarup T; Reguer L; Faber OK; Binder C
Diabetologia; 1981 May; 20(5):530-4. PubMed ID: 7026327
[TBL] [Abstract][Full Text] [Related]
16. Correlations between fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in insulin-treated diabetics.
Gjessing HJ; Matzen LE; Frøland A; Faber OK
Diabetes Care; 1987; 10(4):487-90. PubMed ID: 3304899
[TBL] [Abstract][Full Text] [Related]
17. Persistent insulin secretion, assessed by plasma C-peptide estimation in long-term juvenile diabetics with a low insulin requirement.
Eff C; Faber O; Deckert T
Diabetologia; 1978 Sep; 15(3):169-72. PubMed ID: 359394
[TBL] [Abstract][Full Text] [Related]
18. The effect of acute hyperglycemia on the plasma C-peptide response to intravenous glucagon or to a mixed meal in insulin-dependent diabetes mellitus.
Gjessing HJ; Reinholdt B; Faber OK; Pedersen O
Acta Endocrinol (Copenh); 1991 May; 124(5):556-62. PubMed ID: 2028714
[TBL] [Abstract][Full Text] [Related]
19. Residual B cell function in patients with long-standing NIDDM and its relation to metabolic control and diabetic complications.
Iwase M; Kikuchi M; Nunoi K; Maki Y; Wakisaka M; Wada M; Fujishima M
Endocrinol Jpn; 1988 Dec; 35(6):803-8. PubMed ID: 3074917
[TBL] [Abstract][Full Text] [Related]
20. Parallel dysfunctions of pancreatic A, B and PP cells in insulin dependent diabetes.
Nonaka K; Toyoshima H; Hanafusa T; Tarui S
Endocrinol Jpn; 1980 Dec; 27 Suppl 1():127-33. PubMed ID: 7014203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
